No Data
Bank of America Securities Downgrades Editas Medicine (EDIT) to a Sell
BofA Securities Downgrades Editas Medicine to Underperform
Express News | Editas Medicine Inc : BofA Global Research Cuts to Underperform From Buy; Cuts Price Objective to $1 From $13
Revenues Working Against Editas Medicine, Inc.'s (NASDAQ:EDIT) Share Price Following 34% Dive
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Insider Sellers Might Regret Selling Editas Medicine Shares at a Lower Price Than Current Market Value